机构：[1]Doheny Image Reading Center, Doheny Eye Institute, PO Box 86228, Los Angeles, CA 90086, USA[2]Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA[3]Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Sciences Key, Laboratory, Capital Medical University, Beijing, China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Retina Consultants of Houston, Houston, TX, USA[5]Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, USA
Our purpose was to evaluate the relationship between subfoveal choroidal thickness (SCT) and development of macular atrophy (MA) in eyes with age-related macular degeneration (AMD). This was a prospective, multicenter study. Sixty participants (120 eyes) in the TREX-AMD trial (NCT01648292) with treatment-na < ve neovascular AMD (NVAMD) in at least one eye were included. SCT was measured by certified reading center graders at baseline using spectral domain optical coherence tomography (SDOCT). The baseline SCT was correlated with the presence of MA at baseline and development of incident MA by month 18. Generalized estimating equations were used to account for information from both eyes. Baseline SCT in eyes with MA was statistically significantly less than in those without MA in both the dry AMD (DAMD) (P = 0.04) and NVAMD (P = 0.01) groups. Comparison of baseline SCT between MA developers and non-MA developers revealed a statistically significant difference (P = 0.03). Receiver operating characteristic curve (ROC) analysis showed the cut-off threshold of SCT for predicting the development of MA in cases without MA at baseline was 124 mu m (AUC = 0.772; Sensitivity = 0.923; Specificity = 0.5). Among eyes without MA at baseline, those with baseline SCT ae<currency>124 mu m were 4.3 times more likely to develop MA (Odds ratio: 4.3, 95% confidence interval: 1.6-12, P = 0.005) than those with baseline SCT > 124 mu m. Eyes with AMD and MA had less SCT than those without MA. Eyes with less baseline SCT also appear to be at higher risk to develop MA within 18 months.
基金：
Carl Zeiss Meditec; Optos; AllerganAbbVieAllergan; GenentechRoche HoldingGenentech
第一作者机构：[1]Doheny Image Reading Center, Doheny Eye Institute, PO Box 86228, Los Angeles, CA 90086, USA[2]Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA[3]Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Sciences Key, Laboratory, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Doheny Image Reading Center, Doheny Eye Institute, PO Box 86228, Los Angeles, CA 90086, USA[2]Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
推荐引用方式(GB/T 7714)：
Fan Wenying,Abdelfattah Nizar Saleh,Uji Akihito,et al.Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial[J].GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY.2018,256(3):511-518.doi:10.1007/s00417-017-3888-2.
APA：
Fan, Wenying,Abdelfattah, Nizar Saleh,Uji, Akihito,Lei, Jianqin,Ip, Michael...&on behalf of the TREX-AMD Study Group.(2018).Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY,256,(3)
MLA：
Fan, Wenying,et al."Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial".GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 256..3(2018):511-518
